Sugi Predict

Sugi Predict / Targets / AKT2

AKT2

RAC-beta serine/threonine-protein kinase · P31751 · AKT2 on Sugi Atlas →

92,378 patent compounds predicted against AKT2, 54,356 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL190637 SCHEMBL190637 1.00 20/20
SCHEMBL190846 SCHEMBL190846 1.00 20/20
SCHEMBL190978 SCHEMBL190978 1.00 20/20
SCHEMBL190979 SCHEMBL190979 1.00 20/20
SCHEMBL191072 SCHEMBL191072 1.00 20/20
SCHEMBL191124 SCHEMBL191124 1.00 20/20
SCHEMBL191125 SCHEMBL191125 1.00 20/20
SCHEMBL191220 SCHEMBL191220 1.00 20/20
SCHEMBL191438 SCHEMBL191438 1.00 20/20
SCHEMBL191439 SCHEMBL191439 1.00 20/20
SCHEMBL191446 SCHEMBL191446 1.00 20/20
SCHEMBL191447 SCHEMBL191447 1.00 20/20
SCHEMBL191553 SCHEMBL191553 1.00 20/20
SCHEMBL191554 SCHEMBL191554 1.00 20/20
SCHEMBL191650 SCHEMBL191650 1.00 20/20
SCHEMBL191651 SCHEMBL191651 1.00 20/20
SCHEMBL191652 SCHEMBL191652 1.00 20/20
SCHEMBL191673 SCHEMBL191673 1.00 20/20
SCHEMBL191674 SCHEMBL191674 1.00 20/20
SCHEMBL191808 SCHEMBL191808 1.00 20/20

Clinical trials — most relevant to AKT2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) PHASE2ACTIVE_NOT_RECRUITING
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC PHASE2COMPLETED
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) PHASE2COMPLETED
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) PHASE2ACTIVE_NOT_RECRUITING
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma PHASE1/PHASE2COMPLETED
Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas PHASE2COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
PIK3CA in HER2+ BC and pCR Trial nanUNKNOWN
Duality of Lipids: the Athlete's Paradox nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a AKT2 binder may also engage these)

ProteinNameSimilarity
P47197 — 1.000 P47197 →
Q60823 — 1.000 Q60823 →
Q7ZX15 — 1.000 Q7ZX15 →
Q6IP76 — 1.000 Q6IP76 →
Q9WUA6 — 0.999 Q9WUA6 →
Q98TY9 — 0.997 Q98TY9 →
Q63484 — 0.997 Q63484 →
P31750 — 0.995 P31750 →
AKT3 RAC-gamma serine/threonine-protein kinase 0.995 landscape →
P31748 — 0.991 P31748 →
AKT1 RAC-alpha serine/threonine-protein kinase 0.991 landscape →
P47196 — 0.988 P47196 →
Q01314 — 0.986 Q01314 →
Q39192 — 0.971 Q39192 →
Q6X4A2 — 0.970 Q6X4A2 →
Q2RAX3 — 0.969 Q2RAX3 →
O64812 — 0.969 O64812 →
Q9M9E9 — 0.967 Q9M9E9 →
O70291 — 0.965 O70291 →
Q6ZLP5 — 0.965 Q6ZLP5 →
Q2V452 — 0.964 Q2V452 →
MAPK8 Mitogen-activated protein kinase 8 0.963 landscape →
Q6ZI44 — 0.962 Q6ZI44 →
Q84VQ3 — 0.962 Q84VQ3 →
Q91Y86 — 0.962 Q91Y86 →
Q8AYC9 — 0.961 Q8AYC9 →
P49071 — 0.961 P49071 →
Q90327 — 0.960 Q90327 →
P68181 — 0.960 P68181 →
P49185 — 0.960 P49185 →